• 1. Distribution pattern and allocation of defects in hydrogenated ZnO thin films?
  Vitaly Gurylev,Chung-Yi Su,Tsong-Pyng Perng Phys. Chem. Chem. Phys., 2016,18, 16033-16038
• 2. Distribution and ecological risk assessment of typical antibiotics in the surface waters of seven major rivers, China?
  Environ. Sci.: Processes Impacts, 2021,23, 1088-1100
• 3. Elusive 2-aminofuran Diels–Alder substrates for a straightforward synthesis of polysubstituted anilines?
  Ana G. Neo,Ana Bornadiego,Jesús Díaz,Stefano Marcaccini,Carlos F. Marcos Org. Biomol. Chem., 2013,11, 6546-6555
• 4. Excited state potential energy surfaces and their interactions in FeIVO active sites
  Shaun D. Wong,Edward I. Solomon Dalton Trans., 2014,43, 17567-17577
• 5. Enantiomorphic symmetry breaking in crystallization of molten sodium chlorate?
  Martin R. Ward,Gary W. Copeland,Andrew J. Alexander Chem. Commun., 2010,46, 7634-7636

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Quinolines and derivatives Quinolines and derivatives
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Quinolines and derivatives

Introduction to 2-(4-Methylquinolin-6-yl)acetic acid (CAS No. 1368259-54-4)

2-(4-Methylquinolin-6-yl)acetic acid, identified by the Chemical Abstracts Service Number (CAS No.) 1368259-54-4, is a specialized organic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research. This compound belongs to the quinoline derivatives family, a class of molecules known for their diverse biological activities and potential therapeutic applications. The structural framework of 2-(4-Methylquinolin-6-yl)acetic acid incorporates a quinoline core substituted with a methyl group at the 4-position and an acetic acid moiety at the 6-position, which contributes to its unique chemical properties and biological interactions.

The quinoline scaffold is a privileged structure in drug discovery, with numerous examples of quinoline-based compounds exhibiting antimicrobial, antimalarial, anticancer, and anti-inflammatory effects. The introduction of the methyl group at the 4-position of the quinoline ring in 2-(4-Methylquinolin-6-yl)acetic acid is particularly noteworthy, as it can influence the compound's solubility, metabolic stability, and binding affinity to biological targets. Furthermore, the presence of the acetic acid functional group provides a carboxylic acid moiety that can participate in hydrogen bonding interactions, potentially enhancing the compound's ability to interact with proteins and enzymes.

In recent years, there has been growing interest in quinoline derivatives as scaffolds for developing novel therapeutic agents. The structural features of 2-(4-Methylquinolin-6-yl)acetic acid make it a promising candidate for further investigation in various pharmacological contexts. For instance, studies have suggested that quinoline derivatives can modulate enzyme activity and interfere with pathogenic processes. The specific substitution pattern in 2-(4-Methylquinolin-6-yl)acetic acid may confer selectivity for certain biological pathways, making it a valuable tool for investigating disease mechanisms and developing targeted therapies.

One of the most compelling aspects of 2-(4-Methylquinolin-6-yl)acetic acid is its potential role in addressing unmet medical needs. Current research efforts are focused on identifying new chemical entities that can combat resistant pathogens and modulate chronic inflammatory conditions. The unique structural features of this compound position it as a candidate for developing drugs with improved efficacy and reduced side effects. Additionally, the quinoline core is well-documented for its ability to cross biological membranes, which is crucial for achieving adequate pharmacokinetic profiles.

The synthesis of 2-(4-Methylquinolin-6-yl)acetic acid involves multi-step organic reactions that require precise control over reaction conditions and reagent selection. Advanced synthetic methodologies have been employed to optimize yield and purity, ensuring that the final product meets the stringent requirements for pharmaceutical applications. Techniques such as palladium-catalyzed cross-coupling reactions and regioselective functionalization have been instrumental in constructing the complex framework of this compound.

From a computational chemistry perspective, molecular modeling studies have been conducted to elucidate the binding interactions of 2-(4-Methylquinolin-6-yl)acetic acid with potential biological targets. These studies provide insights into how the compound interacts with enzymes and receptors at an atomic level, guiding the design of analogs with enhanced binding affinity. The integration of experimental data with computational predictions has accelerated the discovery process and allowed researchers to prioritize promising candidates for further validation.

The pharmacological profile of 2-(4-Methylquinolin-6-yl)acetic acid has been preliminarily assessed through in vitro assays. Initial findings suggest that this compound exhibits inhibitory activity against certain enzymes implicated in inflammatory pathways. This activity is particularly relevant given the increasing recognition of inflammation as a central mechanism in various diseases, including cardiovascular disorders and neurodegenerative conditions. Further preclinical studies are warranted to confirm these findings and explore additional therapeutic potentials.

Recent advancements in drug delivery systems have opened new avenues for utilizing compounds like 2-(4-Methylquinolin-6-yl)acetic acid. Nanotechnology-based platforms have been investigated as vehicles for delivering therapeutic agents to target tissues with high specificity and efficiency. The ability of quinoline derivatives to encapsulate within nanoparticles has been exploited to enhance their bioavailability and prolong their circulation time within biological systems.

The regulatory landscape for novel pharmaceutical compounds requires rigorous evaluation to ensure safety and efficacy before clinical translation. Regulatory agencies have established guidelines for assessing the pharmacokinetics, pharmacodynamics, and toxicology of new chemical entities like 2-(4-Methylquinolin-6-yl)acetic acid. Compliance with these regulations is essential for advancing promising candidates into clinical trials and ultimately bringing new treatments to patients.

The future directions for research on 2-(4-Methylquinolin-6-yl)acetic acid include exploring its potential as an intermediate in synthesizing more complex drug candidates. Additionally, investigating its role in combination therapies may uncover synergistic effects that could improve treatment outcomes. Collaborative efforts between academic institutions, pharmaceutical companies, and biotech firms are crucial for translating basic research findings into tangible therapeutic benefits.

In conclusion,2-(4-Methylquinolin-6-yl)acetic acid (CAS No. 1368259-54-4) represents a significant advancement in quinoline-based drug discovery. Its unique structural features, combined with preliminary pharmacological evidence, position it as a promising candidate for further development in medicine. Continued research efforts will be essential to fully realize its therapeutic potential and address unmet medical needs across various disease areas.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)